While other drug pricing reform proposals have been voiced, it remains to be seen whether any plan will materialize in time to be used as a campaign tool for the 2020 election. (Photo: Shutterstock)
A one-two punch has put the drug pricing agenda from the White House down for the count. A judge has blocked one rule that would have forced drug companies to disclose prices in TV ads, and a proposal that would have eliminated drug rebates was abandoned after an outcry that it would have raised seniors' Medicare premiums and cost Medicare millions more for prescription drugs.
According to The Hill, Congress may actually have to step up and take action now that the White House agenda has fizzled. Cutting drug prices has become a bête noire for the president with action stalled on both fronts, particularly since Alex Azar, secretary of Health and Human Services, has been pushing the rebate plan for months.
Meanwhile, drug prices are still on the rise.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Marlene Satter
Marlene Y. Satter has worked in and written about the financial industry for decades.
